Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996427 | 1.00 | MAPK1 (0.44) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL6153394 | 0.81 | RBP4 (0.38) | MAPK1 | |
| SCHEMBL2109651 | 0.78 | RBP4 (0.51) | MAPK1KDM1ATSHRALOX15HDAC1 | |
| SCHEMBL21940364 | 0.76 | HDAC1 (0.49) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL381500 | 0.76 | KDM1A (0.52) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL6970469 | 0.76 | KDM1A (0.52) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL6968834 | 0.76 | KDM1A (0.52) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL6959970 | 0.76 | KDM1A (0.52) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL29993455 | 0.76 | KDM1A (0.52) | MAPK1KDM1ATSHRALOX15ATM | |
| SCHEMBL23902054 | 0.74 | MAPK1 (0.51) | MAPK1KDM1ATSHRALOX15ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SANKYO COMPANY, LIMITED (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1533314-A1 | PROCESS FOR PRODUCING CYCLIC THIOETHER AND SYNTHETIC INTERMEDIATE THEREOF | Sankyo Company, Limited (JP) | 2005-05-25 | — | — | EP | disclosed |
| EP-0987269-B1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | SANKYO CO (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6362179-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | SANKYO COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-0776893-B1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO CO (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0987269-A1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Sankyo Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165037-A1 | Process for producing cyclic thioether and synthetic intermediate thereof | SULT1E1, TST, TMT1A | MAPK1 1770/4885KDM1A 4024/4885TSHR 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.